Abbott Laboratories Boosts FY24 Earnings Outlook - Update
(RTTNews) - While reporting financial results for the second quarter on Thursday, Abbott Laboratories (ABT) provided earnings and adjusted earnings guidance for the third quarter and raised its outlook for the full-year 2024.
For the third quarter, Abbott projects earnings in a range of $0.85 to $0.89 per share and adjusted earnings in a range of $1.18 to $1.22 per share.
On average, 20 analysts polled by Thomson Reuters expect the company to report earnings of $1.10 per share for the quarter. Analysts' estimates typically exclude special items.
Looking ahead to fiscal 2024, the company now projects earnings in a range of $3.30 to $3.40 per share and adjusted earnings in a range of $4.61 to $4.71 per share.
Previously, the company expected earnings in a range of $3.25 to $3.40 per share and adjusted earnings in a range of $4.55 to $4.70 per share.
The Street is looking for earnings of $4.63 per share for the year.
Abbott narrowed its full-year organic sales growth guidance range, excluding COVID-19 testing-related sales, to 9.5 to 10.0 percent, which represents an increase at the midpoint of the range.
On June 14, 2024, the board of directors of Abbott declared a quarterly dividend of $0.55 per share, payable on August 15, 2024 to shareholders of record at the close of business on July 15, 2024.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Abbott Q2 Profit Plunges, Lifts FY26 Adj. EPS View, Backs Sales Forecast; Stock Up 11%
Abbott Says FDA Approves First-of-Its-Kind TriClip Transcatheter Edge-to-edge Repair System
Abbott Laboratories Guides FY24 Adj. EPS In Line With Estimates - Update
Abbott Inks Deal With MAbxience To Commercialize Biosimilar Molecules In Emerging Markets
Abbott Laboratories Reaffirms FY23 Adj. EPS Outlook - Update
Abbott Laboratories Says FDA Approves Assert-IQ Insertable Cardiac Monitor
Abbott Says FDA Approves Spinal Cord Stimulation Devices To Treat Chronic Back Pain
